

Conference Day 1: Tuesday, September 28th 2021

9:00am Chairs Opening Remarks and Setting the Scene

Renae Beaumont, Assistant Professor of Psychology in Clinical Psychiatry, [Weill Cornell Medicine](#)

9:15am Keynote Panel Discussion: How can we Align and Consolidate the Industry to Achieve Collective Success?

The digital therapeutics industry is currently sitting at it's next inflection point with the space winding up to accelerate digital interventions into mainstream healthcare. Ensuring key stakeholders are aligned and in agreement with the future of the space is crucial for this industry to reach its full potential.

- How can we ensure all stakeholders within this industry are aligned towards the same goal?
- How does digital health align with pharma's manufacturing, regulatory and commercial models?
- Where is the divide within digital therapeutics and what will it take to resolve this?
- Which stakeholders can make the most difference in the current industry climate?
- Will consolidation of the industry help accelerate commercial success and provider adoption?
- How can the introduction of digital within healthcare promote health equity?

Moderated by **Kamal Jethwani**, Co-Founder & CEO, [Decimal Health](#)

Innes Meldrum, SVP & Chief Commercial Officer, [Otsuka Pharmaceuticals North America](#)

Seth Feuerstein, Executive Director and Founder, Center for Digital Health and Innovation, [Yale University School of Medicine](#)

Joe Blomeley, EVP, Individual, Public Sector & Mental Health, [Green Shield Canada](#)

Tania Elliott, Chief Medical Officer, Virtual Care, [Ascension](#)

Andrey Ostrovsky, Managing Partner, [Social Innovation Partners](#)

Value

10:05am Panel Discussion: What is it Going to Take to Achieve Complete Coverage for Digital Therapeutics?

The question that no one has cracked just yet - 'How are digital therapeutics going to get paid for'? With numerous market opportunities including payers, employers, digital formularies, OTC and more, this panel will dive into exactly what it will take for digital therapeutics to achieve reimbursement.

- How can DTx companies effectively approach and work with payers for reimbursement?
- What opportunities are there for reimbursement and who are the current success stories?
- How can we streamline the route to reimbursement to enable increased coverage for digital interventions?
- What are the greatest challenges when considering reimbursement for both DTx companies and payers?
- How does coverage differ from prescription and non-prescription digital therapies?
- Are we on the road to national reimbursement for digital therapeutics?

Ryan Lawton, Chief Architect, [Blue Shield of California](#)

Liz Kwo, Deputy Chief Clinical Officer, [Anthem](#)

Liesl Oldstone, VP, Health Economics & Market Access, [AppliedVR](#)

10:45am

Morning Refreshments and Networking

11:15am Fireside Chat: The Role of the DTA in Advancing the Digital Therapeutics Industry

The Digital Therapeutic Alliance are the champions for the DTx industry. Founded and grown by the experts and veterans of the industry, this fireside chat will bring the role of the DTA within the industry to light and demonstrate preliminary findings from an exciting and new undertaking.

- What is the role of the Digital Therapeutics Alliance in advancing the industry?
- What are the current projects DTA is working on to promote regulation, reimbursement and adoption of digital therapeutics?
- Insights into the 'Value Assessment & Implementation Guide' produced by DTA

Debra Reisenethel, Founding CEO, [Freemira, Inc](#) & Chair, [Digital Therapeutics Alliance](#)

Andy Molnar, Chief Executive Officer, [Digital Therapeutics Alliance](#)

Megan Coder, VP of Global Policy, [Digital Therapeutics Alliance](#)

11:45am Presentation: One Year DVG in Germany - Lessons learned and the Path Forward

After pioneering the path to national reimbursement for digital therapies, it's now been one year since Germany unveiled and began its DVG plan. GAIA AG, one of the industry's leading DTx companies, has been enrolled from the very start and will dive into the intricacies of the plan in this presentation.

- What are the findings of the first year of the DVG plan and did it run as expected?
- What can other countries looking to drive their own national reimbursement plan learn from the German DVG plan?
- How can the DVG continue to be refined in the future for increased effectiveness?

Matthias Zenker, Chief Medical Solutions Officer, [GAIA AG](#)

Lina Behrens, Managing Director, [Flying Health](#)

12:10pm Panel Discussion: Understanding the Business of Digital Therapeutics

Digital therapies have proven to demonstrate clinical effectiveness in a healthcare setting and rival clinical outcomes of traditional therapies. However, questions still remain on what economic value digital interventions can bring to healthcare alongside unknowns surrounding business and go-to-market models. This panel will outline the success stories, challenges and insights into the business of digital therapeutics.

- An outline of current business models adopted and created by the digital therapeutics industry.
- How can we demonstrate the economic value of digital therapeutics within the healthcare system?
- Where have we seen success in changing business models to suit the current market opportunities?
- What are the overarching go-to-market challenges that are still being faced within the industry?
- How do business strategies differ between widespread and rare diseases?

Moderated by Christopher Barr, Senior Director, [Simon-Kucher & Partners](#)

Joe Perekupka, Chief Commercial Officer, [EVERSANA](#)
Melinda Decker, Chief Commercial Officer, [Mymee](#)
Julia Strandberg, Chief Commercial Officer, [Pear Therapeutics](#)
Jennifer Laventure, VP, Business Development, [MedRhythms](#)
Elena Mustatea, Chief Executive Officer, [Bold Health](#)

12:50pm Panel Discussion: Understanding the End-to-End Process of Building a Regulated Software as a Medical Device (SaMD)

With the evolution of healthcare, the pressure to enhance and personalize therapeutics has led to pharmaceutical companies moving their focus towards utilizing software as a medical device. However, key challenges remain in the development, maintenance and scalability of SaMD. This panel, led by topic experts and senior pharma exec's, will dive into the end-to-end process of SaMD and the challenges involved.

- What are the opportunities within digital health and where can it aid in streamlining the healthcare system and improving therapeutic development?
- How should biopharma approach digital health technology partnerships to develop a regulated SaMD and what are the evaluation criteria?
- What are the best practices in developing, scaling and maintaining a regulated SaMD?
- How to navigate the regulatory, privacy and security challenges when hosting across global markets?
- What are the key takeaways and lessons learned from biopharma in launching, maintaining and growing a successful SaMD?

Kal Patel, Co-Founder & CEO, [BrightInsight](#)
Dhairya Mehta, Director, Device and Combination Products, [Shire](#)
Karan Arora, Chief Commercial Digital Officer, [AstraZeneca](#)

1:30pm

Lunch

2:35pm Presentation: The Future of Digital Diagnostics: Functional Infrared Thermography

Digital Diagnostics using Functional Infrared Thermography (IRT) is a rapidly moving and promising field. Applications include musculoskeletal injury, inflammation, infection, and cancer detection. Many areas such as skin tumor differentiation and repetitive mechanical stress injury are major problems with inadequate diagnostics. The industry incorporates artificial intelligence, machine learning, edge-based cloud computing, and big data analytics. IRT is currently used in biorisk management, veterinary medicine, and industrial safety.

Greg Licholai, Chief Medical & Information Officer, [PRA Health Sciences, An ICON plc Company](#)

3:00pm Panel Discussion: An Industry Deep-Dive into Digital Therapeutics and Pharma Partnerships

Digital therapeutics and pharma partnerships have been a mainstay of the industry since the industry began. Across a number of partnerships we've witnessed both success and shortcomings. This panel, led by pharma and DTx experts, will dive into how best for these key stakeholders to work together.

- What are the learnings of current and previous DTx/Pharma partnerships?
- What are pharma looking for in a DTx partnership and how best can DTx companies stand above the noise?
- How can we build partnerships that best appreciate the mindset between DTx company and Pharma?
- What considerations need to be made to assure a mutually beneficial partnership is built?
- Is the Pharma/DTx collaborating still a sought after partnership in this space?

Joe Powers, Chief Digital Business Officer, **Otsuka Pharmaceutical North America**

Abhishek Shah, Co-Founder & CEO, **Wellthy Therapeutics**

Peter Quake Pletcher, Partnerships Manager, **Eli Lilly and Company**

Thomas Thestrup, Director, Corporate Business Development & Strategy, **Lundbeck**

Pierre Leurent, Founder & CEO, **Voluntis**

Kuldeep Singh Rajput, Founder & CEO, **Biofourmis**

3:40pm **Presentation: Understanding the Role of CPT Code Reimbursement within Digital Therapeutics**

- How should DTx companies use CPT codes to advance their business?
- How can clinicians use CPT codes to get paid for services associated with DTx products?
- What CPT codes make the most sense for DTx companies to use and promote using by clinicians?

Chris Wasden, Head of HappifyDTx, **Happify Health**

4:05pm **Panel Discussion: Achieving Reimbursement through Employers - The In's and Out's of Employer Partnerships**

In light of the Covid-19 pandemic we've seen an explosion of employers taking considerable steps in allowing employees to take control of their own health. Digital therapies are well positioned to be easily adopted, user friendly and clinically effective and many companies are already seeing success with this route to reimbursement. This panel will dive into the intricacies of achieving reimbursement through employers.

- What are the intricacies of achieving reimbursement for digital health through employers?
- Are we seeing more opportunities to partner with employers in a post-pandemic ecosystem?
- Is employer coverage as sustainable as the seemingly more sought after healthcare insurer?
- Is reimbursement through employers limited to specific disease modalities?
- What can companies do to make their digital product offerings more attractive to employers?

Chris Lento, Head of Healthcare, Strategic Partnerships and Sales, **Noom**

Jonas Duss, US CEO, **Kaia Health**

Chris Roberston, Director of Product Partnership, **Virgin Pulse**

Krishnan Sridharan, President, **Transcarent**

Lucia Savage, Chief Privacy & Regulatory Officer, **Omada Health**

4:45pm

Afternoon Refreshments & Networking

5:15pm **Presentation: Lessons learned: Long Term Retention and Monitoring in DTx Trials**

In this presentation we explore live, case studies of previous digital therapeutic trials and first hand experience with the

importance of consistently capturing long term outcomes through sophisticated patient engagement tools. We'll explore what makes digital therapeutic trials unique in terms of how to handle long term followup and keep patients engaged in data collection.

Adam Samson, Senior Director, Clinical Operations & Customer Success, [Curebase](#)

5:35pm Panel Discussion: Reshaping the Future of Clinical Trials for Digital Therapeutics

Utilizing clinical trials to demonstrate clinical efficacy has been a mainstay within the therapeutic industry for years. However, with the introduction of new digital interventions, these trials are no longer efficient and optimal. This panel, led by the industry experts, will dive into the intricacies of adapting clinical trials specifically for digital therapeutics

- What are the challenges with current clinical trials for digital therapeutics?
- Where can changes be made within the clinic to develop more efficient trials for DTx?
- An insight into decentralized clinical trials and why many digital therapeutics companies are adopting this as the new normal
- How do decentralized clinical trials compare to traditional studies?
- What is the future of clinical trials for digital health interventions?

Kimberly Tableman, Chief Clinical Development Officer, [Castor](#)

Athena Robinson, Chief Clinical Officer, [Woebot Health](#)

Mona Dean, VP, Quality & Regulatory Affairs, [Happify Health](#)

6:15pm Chairs Closing Remarks

Renaë Beaumont, Assistant Professor of Psychology in Clinical Psychiatry, [Weill Cornell Medicine](#)

Close of DTx East 2021 Day 1

Conference Day 2: Wednesday, 29th 2021

9:00am Chairs Opening Remarks and Setting the Scene

Amir Lahav, Digital Healthcare Innovation, Head of Digital R&D, [Mitsubishi Tanabe Pharma Holding America](#)

Provider & Patients

9:05am Panel Discussion: Let's *Really* Put the Patient at the Center: A Panel of Real-Life Users of Leading DTx Products

Digital therapeutics can adapt to patient needs like no other “medicine” that has come before. This approach not only creates a completely novel experience that transforms patient experiences today, but also sets the stage for what the

future of medicine could look like. This panel, featuring early users of DTx, will discuss how they've incorporated this medicine into their lives and advice for both manufactures and other patients considering DTx.

Eddie Martucci, Co-Founder & CEO, [Akili Interactive](#)

More Speakers to be Announced

9:50am **Presentation: How Pharma can Help Patients Achieve Success Through Digital Therapeutics**

- Patient experience is key
- Start with discovering insights into patients' challenges and barriers
- Importance of co-creating with internal and external stakeholders
- Success factors in building evidence-based solutions to help patients achieve success

Deepti Jaggi, Global Head of Patient Insights & Solutions, [Astellas Pharma](#)

10:15am **Panel Discussion: How Can Corporations Make Mental Health Benefits Equitable for Front Line Workers?**

Although early in its lifecycle, digital therapies have extended their reach to end-to-end care for patients that previously were underserved. This panel will dive into how we can continue this trend to ensure equality in not just treatment of patients, but equality and diversity throughout the industry.

Juliette McClendon, Director of Medical Affairs, [Big Health](#)

Jenna Carl, Chief Medical Officer, [Big Health](#)

Keisha Ross, Clinical Psychologist, [Owner & Founder New Horizon Psychological Services, LLC.](#)

Jennifer Paisley, VP, Total Rewards & HR Operations, [Valmont](#)

11:00am **Morning Refreshments & In-Person - Online Networking**

11:30am **Presentation: Building Digital Interventions around the Patient Instead of the Disease – Whole Person Health Through Precision Digital Therapeutics and Radical Personalization**

A Patient's Diagnosis: despite having always followed food and exercise guidelines, this wasn't the first patient to be shocked to learn that 3 of his major arteries were blocked. He was urged to have emergency triple bypass surgery, but he was miffed and steadfastly declined.

Their Purposeful Search: upset that standard 'average based' lifestyle advice had failed him, the patient combined his expertise in tech with MD's and geneticists, and learned that food can be medicine when consumed to a person's unique biology.

Sharing in the Patient's Passion: ten years later, he biked the second highest pass in the Himalayas. The patient had built many successful businesses, but his latest is a passion. Together, he and his team are now working hard to make chronic lifestyle and inflammatory illnesses optional.

Ranjan Sinha, Chief Executive Officer, [Digbi Health](#)

11:55am **Presentation: A Digital Therapeutics Platform for Developing Personalized Medicine**

Learn how Biofourmis's FDA-cleared analytics engine can rapidly assess, build, and commercialize digital therapeutics. The fully customizable, end-to-end solution is designed to identify and prevent significant issues before they occur, reducing risk and optimizing outcomes.

Jaydev Thakkar, Chief Operating Officer, [Biofourmis](#)

David Kiger, Group VP, Digital Therapeutics, [Biofourmis](#)

12:20pm **Panel Discussion: Can Digital Therapeutics Impact the Patient Journey?**

Is it time to rethink what's possible for the patient journey by embracing the use of digital therapeutics?

More than 40% of patients turn to digital resources to manage their health. But from the time of diagnosis through ongoing care and post-treatment, many patients are left to fend for themselves. To help meet this need, pharma companies are employing digital therapeutics to deliver support and improve the patient journey.

Could a patient-centric digital platform, with wide-ranging behavior change support, help to improve adherence and drive greater outcomes? Through greater refinement of processes and deeper understanding of patient actions, digital therapeutics can implement behavioral health strategies to increase adoption by 70%, leading toward healthier outcomes. In this session, learn the best practices of implementing successful behavior change across the patient journey, needed integrations to holistically support patients and how to deliver real value for pharma and patients.

- Understand how digital therapeutics use behavioral science to drive patients toward positive health actions
- Gain insights into the levers of impact throughout the patient journey through integrated digital therapeutics
- Examine how pharma can add digital therapeutics to achieve greater value as part of medication therapy

Omri Shor, Chief Executive Officer, [Medisafe](#)

Ema Offidani, Head of Medical Affairs, [Click Therapeutics](#)

Sarah Ernst, Senior Director, Digital Strategy & Partnering, [Sanofi Ventures](#)

Laura Yecies, Chief Executive Officer, [Bone Health Technologies](#)

1pm

Lunch

2:15pm **Panel Discussion: How can we Drive Provider Wide Adoption of Digital Interventions?**

With digital therapeutics now obtaining reliable reimbursement, scaling throughout the US and beyond and achieving consistent regulatory approval, key challenges remain around adoption by healthcare providers. This panel will dive into exactly what needs to be implemented for provider wide adoption of digital interventions.

- What are the challenges to implementing digital tools into a clinicians workflow?
- How can we best educate providers on the use of digital therapies?
- How can we align with the decision making process within the healthcare system?
- What are the hurdles around data interoperability when implementing DTx into the healthcare system?
- What are some of the success stories we've seen when using digital therapeutics in the clinic?
- When can we expect to see widespread adoption of digital interventions within healthcare?

Maryam Gholami, SVP, Chief Product & Technology Officer, [Providence Digital Innovation Group](#)

Meg Barron, VP, Digital Health Strategy, [American Medical Association](#)

Shaheen Lakhan, SVP, Research & Development, [Click Therapeutics](#)
Kimberly Kushner, Senior Vice President, [SSI Strategy](#)

3:00pm Presentation: The role of digital pills in decentralized clinical trials and remote patient care: Partnership stories

- The role of digital pills and how they can advance patient data and precision of dose levels
- The impact of digital pills on pharma – How pharma companies can benefit from the ability to confirm medication ingestions.
- How partnerships using digital pills in the clinical market can improve the patient experience

Valerie Sullivan, Former President & CEO, [Formerly at etectRx](#)

3:25pm Presentation: Digital Therapeutics and Data Analytics - Transforming the Care Continuum

- Our current care continuum still falls short in incorporating social determinants of health (SDOH), and addressing patient needs before they enter the healthcare system, and after they receive healthcare services.
- Technologies that have historically transformed industries from Financial services to Retail to Media and Entertainment, are now starting to do the same for Healthcare.
- In 2020, healthcare arrived at a tipping point as the epoch called COVID-19 acted as a great catalyst to make digital health mainstream.
- The value of digital tools (such as remote patient monitoring), telehealth, analytics, and human touch and support in healthcare is well understood - what if we could combine them all?
- Collectively, do they have the power to make the optimal care continuum, clarify SDOH and assist in creating a Preventive Health realm?

Kathryn Cook, Sales Director (Population Health), [HealthIO](#); and Adjunct Professor, [OSF Saint Anthony College of Nursing](#)

3:50pm Panel Discussion: DTx as a Completely Different Treatment Modality - From 'One Size Fits Most to One Size Fits All'

- A brief overview of the various new modalities invented by digital therapeutic companies.
- Where can we see these new ways be valuable? In Mymee's case our insights into autoimmunity allowed us to solve for the Covid long haulers.
- When should digital therapeutics companies begin searching for preventative models? This past year the impact of underlying conditions have been amplified.

Mette Dhyrberg, Founder & CEO, [Mymee](#)
Acacia Parks, Chief Science Officer, [Happify Health](#)
Everett Crosland, Chief Commercial Officer, [Cognito Therapeutics](#)
Kristian Ranta, Founder & CEO, [Meru Health](#)
Adam Dakin, Managing Director, [Dreamit Ventures](#)
Jennifer Gendron, Chief Commercial Officer, [Koa Health](#)

4:30pm

Afternoon Refreshments & Networking

<p>5:00pm Presentation: Enabling Patients to take Control of their Healthcare - Introducing Transcarent</p> <ul style="list-style-type: none"> Introducing Transcarent - An insight into how Transcarent aims to inform patients and enable them to take control of their own health What impact can this system have on the patient's journey within healthcare? <p>Krishnan Sridharan, President, Transcarent Marin Hoffman, VP, Member Success, Transcarent</p>
<p>5:25pm Presentation: An FDA Update on the Regulation of Digital Therapeutics</p> <p>Ian Marcus, Team Lead, FDA</p>
<p>5:50pm Chairs Closing remarks</p> <p>Amir Lahav, Digital Healthcare Innovation, Head of Digital R&D, Mitsubishi Tanabe Pharma America</p>
<p>Close of DTx East 2021 Day 2</p>

<p>Conference Day 3: Thursday, 30th September</p>
<p>9:00am Chairs Opening Remarks and Setting the Scene</p> <p>Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics</p>
<p>The Future of Digital Therapeutics</p>
<p>9:05am Keynote Fireside Chat: The Next Generation of Digital Therapeutics for Mental Health</p> <p>Through a close collaboration between SilverCloud Health and Microsoft Research, how we understand and deliver digital mental health solutions is evolving fast. This fireside chat will present the current projects we are working on, touching on some of the following issues which will drive digital solutions into the future:</p> <ul style="list-style-type: none"> Developing machine learning models using big data which aim to further understand engagement and personalise the experience for the user Applying deep-learning models in research, and how a tool which predicts clinical outcomes goes from an idea, to a large-scale trial, to real-world deployment Building treatment-recommendation systems that optimise the way users interact with the online program by identifying which content leads to better outcomes <p>Jorge Palacios, Senior Digital Health Scientist, Silvercloud Health Anja Thieme, Senior Researcher, Microsoft Derek Richards, Chief Science Officer, SilverCloud Health Angel Enrique, Senior Digital Health Scientist, SilverCloud Health</p>

9:45am **Panel Discussion: The Role of Digital Therapeutics - A Multistakeholder Perspective**

Digital therapeutics are already seeing a fair amount of traction amongst consumers as well as physicians displaying similar openness to the emerging category.

That said, there are still challenges since different stakeholders approach the space with different perspectives, expectation of value and agendas. Many solutions grapple with “last mile” challenges, and insufficient analysis of sometimes-conflicting stakeholder needs. It is important to adopt, early-on, effective stakeholder engagement strategies and rigorous partnerships to demonstrate value to all stakeholders.

In this session we will cover multiple stakeholder perspectives on Digital Therapeutics and what attributes are important for them to demonstrate the value of Digital Therapeutics.

- Understanding key aspects for physicians and provider adoption of digital therapeutics
- What value do you need to demonstrate and how do you deliver this to payers?
- A discussion on value and strategies of early stakeholder engagement to ensure its a ‘win-win’ for all stakeholders by crafting optimal value stories

Shailja Dixit, Chief Executive Officer, **Curio**

Jian Jenny Tang, Assistant Professor of Obstetrics & Gynaecology, **Mount Sinai School of Medicine**

Corrado Panno, VP, Business Development, **Magellan Health**

10:25am **Presentation: A Digital Health Habit: Utilizing AI and ML to ‘Sharpen our Tools’ - A Welldoc Case Study**

- An update on Welldoc’s IDEA framework for maximizing value of digital health data
- Insights into preliminary findings of the utilizing data science and AI within DTx to advance the patients digital health journey towards personalized, actionable insights
- How has the IDEA framework helped patients and providers take the next step towards personalized healthcare?

Anand Iyer, Chief Strategy Officer, **Welldoc**

10:50am **Morning Refreshments & Networking**

11:20am **Presentation: Scaling Digital Therapeutics within the Japanese Market - A Case Study**

With the US and European markets seemingly the focus for many digital therapeutics scaling efforts, there are a number of unknowns regarding the opportunities and challenges in scaling within Japan, the 3rd largest biopharma healthcare market. This presentation will dive into the requirements to successfully scale within Japan and underpin key learnings from a successful expansion within this market.

- A discussion into the regulatory and clinical pathways
- What are the corporate development and reimbursement opportunities available for digital therapeutics within Japan?

- How can you best identify the right partner from expansion within the Asian market?
- What are the product development and UX/UI aspects that need to be considered?

Kenichiro Nishii, Lead, Regulatory Affairs & Business Development, [CureApp](#)

Vasyl Pyrozhyk, VP, Healthcare, [Sumitomo Mitsui Banking Corporation](#)

11:45am **Fireside Chat: The Next Generation of Digital Therapeutics - The bleeding edge of where technology meets biology**

The field of digital therapeutics is ever evolving and pushing the limits of what digital interventions are capable of. This panel, led by those spearheading a new generation of digital interventions, will dive into the intricacies of using digital tools for disease modification and the profound effect this can have on healthcare.

- An discussion focused on utilizing digital therapeutics for disease modification
- How are these next-gen approaches giving rise to a new evolution of digital therapeutics?
- What impact can these novel therapies have on the healthcare system?
- An insight into new data released for disease-modifying DTx solutions
- Are we heading towards a division of digital therapeutics into two separate industries?

Brent Vaughan, Chief Executive Officer, [Cognito Therapeutics](#)

Owen McCarthy, President & Co-Founder, [MedRhythms](#)

12:20pm **Panel Discussion: What Major Steps are Needed for Digital within Healthcare to Break Through the 'Glass Ceiling'**

After three days of all things digital therapeutics, this panel will dive into the 'What's Next' for the industry with key takeaways and learnings around commercialisation, regulation, R&D and more to ensure you're fully caught up on the future goals of the industry when you get back to the office!

- What are the biggest challenges that need to be addressed for the DTx industry to stay on this upward trend?
- Which industry stakeholder plays the biggest part in its success right now?
- How much of an impact can digital therapeutics have on the healthcare system?
- Is the expansion beyond a single program into multiple care pathways the right step forward?
- What will define the success of the digital therapeutics industry moving forward?

Alex Waldron, Chief Executive Officer, [Wellinks](#)

Sean Duffy, Co-Founder & CEO, [Omada Health](#)

Chihiro Hosoya, Head of Venture Management and Business Development, Rx+ Business Accelerator, [Astellas](#)

Neil Leibowitz, Chief Medical Officer, [Beacon Health Options](#)

Eric Buffkin, President & CEO, [etectRx](#)

1pm **Chairs Closing Remarks**

Abhishek Shah, Co-Founder & CEO, [Wellthy Therapeutics](#)

1:05pm

Post Event Networking

Close of DTx East 2021